Muller Fabbri (photo), MD, PhD, of the Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles (CHLA), has been awarded $1.9 million by the National Cancer Institute of the NIH to further his research on neuroblastoma – the third most common type of childhood cancer. The research will focus on a completely new strategy targeting immune cells that contribute to disease progression with a goal toward the development of more potent immunotherapies to improve the outcomes for children with this disease. Neuroblastoma (NB) is a type of solid tumor that starts in immature nerve cells of the sympathetic nervous system. While NB is one of the most common types of pediatric cancer, it is still very rare. Out of the 13,000 children who are diagnosed with cancer each year, only about 650-700 are diagnosed with NB. The disease primarily occurs in children younger than age 10 and is most common in infants and very young children. “My research project is based on the fact that sometimes cancer cells are able to hijack the immune system and use it to their advantage,” said Dr. Fabbri.
Login Or Register To Read Full Story